Da Silva JFM, Garden SJ, Pinto AC. The chemistry of isatins: a review from 1975 to 1999. J Braz Chem Soc. 2001;12:273–324.

Article  Google Scholar 

Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Tuntland T, Zhang K, Karanewsky D, He Y. Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2. Bioorg Med Chem Lett. 2006;16:2109–12.

Article  CAS  PubMed  Google Scholar 

Pandeya SN, Smitha S, Jyoti M, Sridhar SK. Biological activities of isatin and its derivatives. Acta Pharm. 2005;55:27–46.

CAS  PubMed  Google Scholar 

Singh H, Singh JV, Gupta MK, Saxena AK, Sharma S, Nepali K, Bedi P. Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: design, synthesis, biological investigation and docking studies. Bioorg Med Chem Lett. 2017;27:3974–9.

Article  CAS  PubMed  Google Scholar 

Sharma S, Gupta MK, Saxena AK, Bedi PMS. Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: design, synthesis, biological evaluation and molecular modeling studies. Bioorg Med Chem. 2015;23:7165–80.

Article  CAS  PubMed  Google Scholar 

Sharma M, Sharma S, Buddhiraja A, Saxena AK, Nepali K, Bedi PMS. Synthesis and cytotoxicity studies of 3, 5-diaryl N-acetyl pyrazoline-isatin hybrids. Med Chem Res. 2014;23:4337–44.

Article  CAS  Google Scholar 

Nepali K, Sharma S, Sharma M, Bedi PM, Dhar KL. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. Eur J Med Chem. 2014;77:422–87.

Article  CAS  PubMed  Google Scholar 

Wang J, Yun D, Yao J, Fu W, Huang F, Chen L, Wei T, Yu C, Xu H, Zhou X, Huang Y, Wu J, Qiu P, Li W. Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds. Eur J Med Chem. 2018;144:493–503.

Article  CAS  PubMed  Google Scholar 

Xu Z, Zhang S, Gao C, Fan J, Zhao F, Lv ZS, Feng LS. Isatin hybrids and their anti-tuberculosis activity. Chinese Chem Lett. 2017;28:159–67.

Article  CAS  Google Scholar 

Li W, Zhao SJ, Gao F, Lv ZS, Tu JY, Xu Z. Synthesis and in vitro anti‐Tumor, anti‐mycobacterial and anti‐HIV activities of Diethylene‐Glycol‐Tethered Bis‐Isatin derivatives. ChemistrySelect. 2018;3:10250–4.

Article  CAS  Google Scholar 

Devale TL, Parikh J, Miniyar P, Sharma P, Shrivastava B, Murumkar P. Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Chem. 2017;70:256–66.

Article  CAS  PubMed  Google Scholar 

Chiyanzu I, Clarkson C, Smith PJ, Lehman J, Gut J, Rosenthal PJ, Chibale K. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Bioorg Med Chem. 2005;13:3249–61.

Article  CAS  PubMed  Google Scholar 

Thakur RK, Joshi P, Baranwal P, Sharma G, Shukla SK, Tripathi R, Tripathi RP. Synthesis and antiplasmodial activity of glyco-conjugate hybrids of phenylhydrazono-indolinones and glycosylated 1, 2, 3-triazolyl-methyl-indoline-2,3-diones. Eur J Med Chem. 2018;155:764–71.

Article  CAS  PubMed  Google Scholar 

Zhang G-F, Liu X, Zhang S, Pan B, Liu ML. Ciprofloxacin derivatives and their antibacterial activities. Eur J Med Chem. 2018;146:599–612.

Article  CAS  PubMed  Google Scholar 

Zhang G-F, Zhang S, Pan B, Liu X, Feng LS. 4-quinolone derivatives and their activities against Gram positive pathogens. Eur J Med Chem. 2018;143:710–23.

Article  CAS  PubMed  Google Scholar 

Bergman J, Lindström J-O, Tilstam ULF. The structure and properties of some indolic constituents in Couroupita guianensis aubl. Tetrahedron. 1985;41:2879–81.

Article  CAS  Google Scholar 

Guo H. Isatin derivatives and their anti-bacterial activities. Eur J Med Chem. 2019;164:678–88.

Article  CAS  PubMed  Google Scholar 

Singh AK, Kumar A, Singh H, Sonawane P, Paliwal H, Thareja S, Pathak P, Grishina M, Jaremko M, Emwas AH, Yadav JP, Verma A, Khalilullah H, Kumar P. Concept of hybrid drugs and recent advancements in anticancer hybrids. Pharmaceuticals. 2022;15:1071.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Z, Zhang D, Zhou Y, Wang F, Xin A, Gao F, Wang P, Zhang P. The anti-lung cancer activity of propylene tethered dihydroartemisinin-isatin hybrids. Arab J Chem. 2022;15:103721.

Article  CAS  Google Scholar 

Wang Y, Ding R, Tai Z, Hou H, Gao F, Sun X. Artemisinin-isatin hybrids with potential antiproliferative activity against breast cancer. Arab J Chem. 2022;15:103639.

Article  CAS  Google Scholar 

Hou H, Qu B, Su C, Hou G, Gao F. Design, synthesis and anti-lung cancer evaluation of 1,2,3-Triazole tethered dihydroartemisinin-isatin hybrids. Front Pharmacol. 2021;12:801580.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong M, Zheng G, Gao F, Li M, Zhong C. Three-carbon linked dihydroartemisinin-isatin hybrids: design, synthesis and their antiproliferative anticancer activity. Front Pharmacol. 2022;13:834317.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Ferlay J, Colombet M, Soerjomataram I, Perkin DM, Pineros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33588.

Ding Z, Zhou M, Zeng C. Recent advances in isatin hybrids as potential anticancer agents. Arch Pharm. 2020;353:1900367.

Article  CAS  Google Scholar 

Sharma K, Suresh PS, Mullangi R, Srinivas NR. Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors–review of assay methodologies and perspectives. Biomed Chromatogr. 2015;29:803–34.

Article  CAS  PubMed  Google Scholar 

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today. 2020;25:406–13.

Article  CAS  PubMed  Google Scholar 

Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, et al. Identification and characterization of an irreversible inhibitor of CDK2. Chem Biol. 2015;22:1159–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Isoldi MC, Visconti MA, Castrucci AMdeL. Anti-cancer drugs: molecular mechanisms of action. Mini Rev Med Chem. 2005;5:685–95.

Article  CAS  PubMed  Google Scholar 

Gahtori R, Tripathi AH, Kumari A, Negi N, Paliwal A, Tripathi P, et al. Anticancer plant-derivatives: deciphering their oncopreventive and therapeutic potential in molecular terms. Futur J Pharm Sci. 2023;9:14.

Article  Google Scholar 

Aneja B, Khan NS, Khan P, Queen A, Hussain A, Rehman MT, et al. Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis. Eur J Med Chem. 2019;163:840–52.

Article  CAS  PubMed  Google Scholar 

Ferraz de Paiva RE, Vieira EG, Rodrigues da Silva D, Wegerma